0001193125-17-005220.txt : 20170109 0001193125-17-005220.hdr.sgml : 20170109 20170109085055 ACCESSION NUMBER: 0001193125-17-005220 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170109 DATE AS OF CHANGE: 20170109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Holdings, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 17515932 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 FORMER COMPANY: FORMER CONFORMED NAME: COLUMBIA HCA HEALTHCARE CORP DATE OF NAME CHANGE: 20000502 8-K 1 d286165d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 9, 2017

 

 

HCA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

  37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02. Results of Operations and Financial Condition.

On January 9, 2017, HCA Holdings, Inc. (the “Company”) issued a press release previewing its fiscal 2016 results. The text of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information set forth in Item 2.02 and Exhibit 99.1 is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit 99.1    Press Release, dated January 9, 2017.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HOLDINGS, INC.
 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: January 9, 2017


EXHIBIT INDEX

 

Exhibit 99.1    Press Release, dated January 9, 2017.
  
EX-99.1 2 d286165dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

    FOR IMMEDIATE RELEASE
INVESTOR CONTACT:     MEDIA CONTACT:
Mark Kimbrough     Ed Fishbough
615-344-2688     615-344-2810

HCA Previews 2016 Operating Results

Nashville, Tenn., January 9, 2017 – HCA Holdings, Inc. (NYSE: HCA) today announced it expects Income before income taxes to be approximately $4.5 billion and Adjusted EBITDA to be approximately $8.2 billion for the year ended December 31, 2016. The Company anticipates reporting fourth quarter 2016 results of operations and guidance for 2017 on January 31, 2017. A table reconciling Income before income taxes to Adjusted EBITDA is included in this release.

Same facility admissions for the fourth quarter of 2016 are expected to increase approximately 1.6 percent, same facility equivalent admissions are expected to increase approximately 1.5 percent and same facility emergency room visits are expected to increase approximately 1.6 percent from the prior year’s fourth quarter.

The Company is scheduled to present Monday, January 9, 2017 at 8:00 am (PST) at the J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. A link to the live audio webcast is available and copies of the related presentation materials will be available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include statements that do not relate solely to historical or current facts and are subject to finalization of the Company’s fourth quarter financial and accounting procedures. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (2) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education


Reconciliation Act (collectively, the “Health Reform Law”), including the effects of any repeal of, or changes to, the Health Reform Law, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, (3) the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011 (the “BCA”), and related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (4) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (5) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (6) possible changes in Medicare, Medicaid and other state programs, including Medicaid upper payment limit programs or waiver programs, that may impact reimbursements to health care providers and insurers, (7) the highly competitive nature of the health care business, (8) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under managed care agreements, the ability to enter into and renew managed care provider agreements on acceptable terms and the impact of consumer driven health plans and physician utilization trends and practices, (9) the efforts of insurers, health care providers and others to contain health care costs, (10) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (11) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (12) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (13) changes in accounting practices, (14) changes in general economic conditions nationally and regionally in our markets, (15) the emergence and effects related to infectious diseases; (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of potential cybersecurity incidents or security breaches, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology, and (23) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2015 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA” as used throughout this release refer to HCA Holdings, Inc. and its affiliates.


HCA Holdings, Inc.

Supplemental Non-GAAP Disclosures

2016 Operating Results Forecast

(Dollars in millions)

 

     For the Year Ended  
     December 31, 2016  

Income before income taxes

   $ 4,500   

Gains on sales of facilities

     (25

Losses on retirement of debt

     5   

Legal claim costs

     45   
  

 

 

 

Income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs (a)

     4,525   

Depreciation and amortization

     1,965   

Interest expense

     1,710   
  

 

 

 

Adjusted EBITDA (a)

   $ 8,200   
  

 

 

 

The Company’s forecasted operating results are based on current expectations and are subject to finalization of the Company’s fourth quarter financial and accounting procedures.

 

(a) Income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA as primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and GAAP income before income taxes) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. Gains on sales of facilities, losses on retirement of debt and legal claim costs are very difficult to predict, can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to income before income taxes or net income attributable to HCA Holdings, Inc., as a measure of operating performance, or cash flows from operating, investing and financing activities, as a measure of liquidity. Because income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, income before income taxes, excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

GRAPHIC 3 g286165img1.jpg GRAPHIC begin 644 g286165img1.jpg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end